InSphero at the JSOT 2025
Join us at the JSOT 2025 in Okinawa, Japan. This premier event for toxicology professionals is the perfect opportunity to explore the latest advancements in safety science. We’re excited to connect with the Japanese toxicology community and showcase how our 3D InSight™ Human Tissue Platforms.
Don’t miss out on all the exciting activities we’ve planned during JSOT 2025, happening from Wednesday, July 2, to Friday, July 4. We can’t wait to connect with you there!
Quick navigation
Meet our Team at the JSOT 2025


Paul Edgard Clémençon, MBA
Chief Business Officer
Paul Edgard Clémençon, MBA
Chief Business Officer
A seasoned commercial leader with 18+ years of experience in senior sales and marketing roles in small and large corporations. Paul holds a chemistry degree from the University of Applied Sciences of Northwestern Switzerland and an Executive MBA from the University of Zurich.Prior to joining InSphero, Paul served as VP of Strategic Partnerships Europe at eMolecules Inc., a San Diego-based growth company providing solutions for drug discovery to big pharma, biotech, and academic institutions.




Anna Borgström, PhD
Deputy VP Liver Safety
Anna Borgström, PhD
Deputy VP Liver Safety
Anna Borgström has a versatile scientific background with over 10 years’ experience of working in the field of cell and molecular biology at the crossroad between cell-based assays, cancer biology and diagnostic assay development. In early 2022 she joined InSphero as Senior Scientist and Deputy VP Liver Safety team, working as scientific lead and customer-based service studies and numerous R&D projects. In her role at InSphero she is determined to drive the development of next-generation testing methods for drug toxicity and to close the gap between in vivo and in vitro testing, by providing solutions for liver safety questions through the application of 3D liver models as an alternative to animal testing.


Find us at Cosmo Bio booth #86
Visit Cosmo Bio booth #86 and discover our 3D InSight™ Liver Safety - Practical, Physiological & Cost-effective 3D In Vitro Solutions for DILI Assessment
Scientific Talk at the JSOT 2025
Evaluation of a high-throughput microphysiological liver system for hepatotoxicity screening early in drug discovery
Date: Wednesday, 2 July, 2025 | 16:00 - 17:30 PM
Room: 1


Anna Borgström, PhD
Deputy VP Liver Safety
Anna Borgström, PhD
Deputy VP Liver Safety
Anna Borgström has a versatile scientific background with over 10 years’ experience of working in the field of cell and molecular biology at the crossroad between cell-based assays, cancer biology and diagnostic assay development. In early 2022 she joined InSphero as Senior Scientist and Deputy VP Liver Safety team, working as scientific lead and customer-based service studies and numerous R&D projects. In her role at InSphero she is determined to drive the development of next-generation testing methods for drug toxicity and to close the gap between in vivo and in vitro testing, by providing solutions for liver safety questions through the application of 3D liver models as an alternative to animal testing.


Poster at the JSOT 2025
Physiological liver microtissue 384-well microplate system for preclinical hepatotoxicity assessment of therapeutic small molecule drugs
Date: Friday, 4 July, 2025 | 13:30 - 14:30 PM
Poster number: P-389


Anna Borgström, PhD
Deputy VP Liver Safety
Anna Borgström, PhD
Deputy VP Liver Safety
Anna Borgström has a versatile scientific background with over 10 years’ experience of working in the field of cell and molecular biology at the crossroad between cell-based assays, cancer biology and diagnostic assay development. In early 2022 she joined InSphero as Senior Scientist and Deputy VP Liver Safety team, working as scientific lead and customer-based service studies and numerous R&D projects. In her role at InSphero she is determined to drive the development of next-generation testing methods for drug toxicity and to close the gap between in vivo and in vitro testing, by providing solutions for liver safety questions through the application of 3D liver models as an alternative to animal testing.

